
Regeneron Pharmaceuticals and Teva Pharmaceuticals had only just agreed a deal worth a potential $2.6 billion to co-develop Regeneron’s fasinumab …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

